These have been used as maintenance therapy in patients with colitis, showing promising results for clinical remission; furthermore, in animal models, it has been observed that they lead to the inhibition of NF-κB, IL-1β, and TNF-α expression through the TLR4-NF-κB signaling pathway. Here, NFKB1 is linked to colitis.